[go: up one dir, main page]

MX2018012223A - Formulaciones liquidas de fosfaplatino. - Google Patents

Formulaciones liquidas de fosfaplatino.

Info

Publication number
MX2018012223A
MX2018012223A MX2018012223A MX2018012223A MX2018012223A MX 2018012223 A MX2018012223 A MX 2018012223A MX 2018012223 A MX2018012223 A MX 2018012223A MX 2018012223 A MX2018012223 A MX 2018012223A MX 2018012223 A MX2018012223 A MX 2018012223A
Authority
MX
Mexico
Prior art keywords
liquid formulations
phosphaplatin
pyrodach
ready
preparation
Prior art date
Application number
MX2018012223A
Other languages
English (en)
Other versions
MX390441B (es
Inventor
d luke Wayne
Ames Tyler
Original Assignee
Phosplatin Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosplatin Therapeutics Llc filed Critical Phosplatin Therapeutics Llc
Publication of MX2018012223A publication Critical patent/MX2018012223A/es
Publication of MX390441B publication Critical patent/MX390441B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones farmacéuticas de compuestos de fosfaplatino, en particular formulaciones liquidas estables amortiguadas de pirodach-2 listas para usar en el tratamiento de diversos tipos de cáncer, y métodos de preparación.
MX2018012223A 2016-04-06 2017-04-05 Formulaciones liquidas de fosfaplatino. MX390441B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319047P 2016-04-06 2016-04-06
PCT/US2017/026139 WO2017176880A1 (en) 2016-04-06 2017-04-05 Phosphaplatin liquid formulations

Publications (2)

Publication Number Publication Date
MX2018012223A true MX2018012223A (es) 2019-05-30
MX390441B MX390441B (es) 2025-03-04

Family

ID=60000715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012223A MX390441B (es) 2016-04-06 2017-04-05 Formulaciones liquidas de fosfaplatino.

Country Status (18)

Country Link
US (1) US11154529B2 (es)
EP (1) EP3439650A4 (es)
JP (3) JP7634341B2 (es)
KR (1) KR102419247B1 (es)
CN (1) CN109310663B (es)
AU (1) AU2017246883B2 (es)
CA (1) CA3020166A1 (es)
CL (1) CL2018002848A1 (es)
CO (1) CO2018011420A2 (es)
EA (1) EA039525B1 (es)
IL (1) IL262066A (es)
MX (1) MX390441B (es)
MY (1) MY199547A (es)
PH (1) PH12018502139A1 (es)
SG (1) SG11201808717QA (es)
TW (1) TWI798175B (es)
WO (1) WO2017176880A1 (es)
ZA (1) ZA201806530B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808717QA (en) * 2016-04-06 2018-11-29 Phosplatin Therapeutics Llc Phosphaplatin liquid formulations
WO2018129257A1 (en) 2017-01-06 2018-07-12 Phosplatin Therapeutics Llc Phosphaplatin compounds as therapeutic agents for treatment of bone blood cancers
EP4232044A1 (en) * 2020-10-20 2023-08-30 Promontory Therapeutics Inc. Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
DK2575802T3 (en) * 2010-06-04 2017-01-09 Univ Ohio Phosphaplatiner and use thereof for the treatment of cancer
US20130236568A1 (en) * 2011-01-12 2013-09-12 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
WO2013052839A1 (en) 2011-10-05 2013-04-11 Bose Rathindra N Efficient processes for large scale preparation of phosphaplatins antitumor agents
US9012669B2 (en) * 2011-10-05 2015-04-21 The University Of Houston System Efficient processes for large scale preparation of phosphaplatins antitumor agents
SI3202769T1 (sl) * 2012-05-24 2020-02-28 Phosplatin Therapeutics Llc Postopek čiščenja za fosfaplatinove spojine
SG11201808717QA (en) * 2016-04-06 2018-11-29 Phosplatin Therapeutics Llc Phosphaplatin liquid formulations

Also Published As

Publication number Publication date
US20200323810A1 (en) 2020-10-15
MX390441B (es) 2025-03-04
EP3439650A4 (en) 2019-12-11
EA039525B1 (ru) 2022-02-07
AU2017246883B2 (en) 2023-02-09
NZ747321A (en) 2025-05-02
IL262066A (en) 2018-11-29
AU2017246883A1 (en) 2018-11-08
EA201892157A1 (ru) 2019-04-30
SG11201808717QA (en) 2018-11-29
JP2025060745A (ja) 2025-04-10
TW201737920A (zh) 2017-11-01
MY199547A (en) 2023-11-06
KR102419247B1 (ko) 2022-07-11
PH12018502139A1 (en) 2019-09-23
TWI798175B (zh) 2023-04-11
KR20180133889A (ko) 2018-12-17
US11154529B2 (en) 2021-10-26
EP3439650A1 (en) 2019-02-13
JP2019510831A (ja) 2019-04-18
CN109310663B (zh) 2022-05-31
JP2023014110A (ja) 2023-01-26
JP7634341B2 (ja) 2025-02-21
BR112018070603A2 (pt) 2019-02-05
CA3020166A1 (en) 2017-10-12
WO2017176880A1 (en) 2017-10-12
CN109310663A (zh) 2019-02-05
CL2018002848A1 (es) 2018-12-21
ZA201806530B (en) 2019-07-31
CO2018011420A2 (es) 2019-02-08

Similar Documents

Publication Publication Date Title
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX378273B (es) Compuestos activos hacia bromodominios.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX421186B (es) Constructos de anticuerpos.
CL2015002897A1 (es) Inhibidores de bace1
CL2015002835A1 (es) Nuevos derivados de piridina
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX391040B (es) Formulacion de alta concentracion.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
EA202090270A1 (ru) Новые замещенные производные ксантина
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CY1124057T1 (el) Διαμορφωτες υποδοχεων χ ηπατος (lxr)
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.